Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
Minimal Rectal Toxicity in the Setting of Comorbid Crohn's Disease Following Prostate Cancer Radiotherapy with a Hydrogel Rectal Spacer.

Cureus

Singh R, Jackson PS, Blake M, Cutlip J, Sharma S.
PMID: 28983442
Cureus. 2017 Aug 01;9(8):e1533. doi: 10.7759/cureus.1533.

We present one of the first cases of a prostate cancer (PCa) patient with inflammatory bowel disease (IBD) treated with intensity-modulated radiotherapy (IMRT) and a hydrogel rectal spacer. A 73-year-old male with a past medical history significant for Crohn's...

Cite
Singh R, Jackson PS, Blake M, et al. Minimal Rectal Toxicity in the Setting of Comorbid Crohn's Disease Following Prostate Cancer Radiotherapy with a Hydrogel Rectal Spacer. Cureus. 2017;9(8):e1533doi: 10.7759/cureus.1533.
Singh, R., Jackson, P. S., Blake, M., Cutlip, J., & Sharma, S. (2017). Minimal Rectal Toxicity in the Setting of Comorbid Crohn's Disease Following Prostate Cancer Radiotherapy with a Hydrogel Rectal Spacer. Cureus, 9(8), e1533. https://doi.org/10.7759/cureus.1533
Singh, Raj, et al. "Minimal Rectal Toxicity in the Setting of Comorbid Crohn's Disease Following Prostate Cancer Radiotherapy with a Hydrogel Rectal Spacer." Cureus vol. 9,8 (2017): e1533. doi: https://doi.org/10.7759/cureus.1533
Singh R, Jackson PS, Blake M, Cutlip J, Sharma S. Minimal Rectal Toxicity in the Setting of Comorbid Crohn's Disease Following Prostate Cancer Radiotherapy with a Hydrogel Rectal Spacer. Cureus. 2017 Aug 01;9(8):e1533. doi: 10.7759/cureus.1533. PMID: 28983442; PMCID: PMC5624568.
Copy Download .nbib Format: NLM
A first-year course focused on the patient, the physician, and the community.

Academic medicine : journal of the Association of American Medical Colleges

Antonelli MA, Cutlip AC.
PMID: 10676224
Acad Med. 1999 May;74(5):599-600. doi: 10.1097/00001888-199905000-00074.

No abstract available.

Cite
Antonelli MA, Cutlip AC. A first-year course focused on the patient, the physician, and the community. Acad Med. 1999;74(5):599-600doi: 10.1097/00001888-199905000-00074.
Antonelli, M. A., & Cutlip, A. C. (1999). A first-year course focused on the patient, the physician, and the community. Academic medicine : journal of the Association of American Medical Colleges, 74(5), 599-600. https://doi.org/10.1097/00001888-199905000-00074
Antonelli, M A, and Cutlip, A C. "A first-year course focused on the patient, the physician, and the community." Academic medicine : journal of the Association of American Medical Colleges vol. 74,5 (1999): 599-600. doi: https://doi.org/10.1097/00001888-199905000-00074
Antonelli MA, Cutlip AC. A first-year course focused on the patient, the physician, and the community. Acad Med. 1999 May;74(5):599-600. doi: 10.1097/00001888-199905000-00074. PMID: 10676224.
Copy Download .nbib Format: NLM
First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Bonan R, Popma JJ, Cutlip DE, Fitzgerald P, Prpic R, Kuntz RE.
PMID: 19758897
EuroIntervention. 2005 Aug;1(2):157-64.

AIMS: The Endeavor I study was the first clinical study evaluating the safety and feasibility of the Endeavor stent system in the treatment of symptomatic coronary artery disease. The Endeavor Stent System comprises a new cytostatic, antiproliferative and immunosuppressive...

Cite
Meredith IT, Ormiston J, Whitbourn R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention. 2005;1(2):157-64
Meredith, I. T., Ormiston, J., Whitbourn, R., Kay, I. P., Muller, D., Bonan, R., Popma, J. J., Cutlip, D. E., Fitzgerald, P., Prpic, R., & Kuntz, R. E. (2005). First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 1(2), 157-64.
Meredith, Ian T, et al. "First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial." EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology vol. 1,2 (2005): 157-64.
Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Bonan R, Popma JJ, Cutlip DE, Fitzgerald P, Prpic R, Kuntz RE. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention. 2005 Aug;1(2):157-64. PMID: 19758897.
Copy Download .nbib Format: NLM
Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE).

Cardiovascular revascularization medicine : including molecular interventions

Colleran R, Joner M, Cutlip D, Urban P, Maeng M, Jauhar R, Barakat M, Michel JM, Mehran R, Kirtane AJ, Maillard L, Kastrati A, Byrne RA.
PMID: 33608239
Cardiovasc Revasc Med. 2021 Jan 22; doi: 10.1016/j.carrev.2021.01.022. Epub 2021 Jan 22.

BACKGROUND/PURPOSE: A coronary stent with thromboresistant and pro-healing properties such as the polymer polyzene F-coated (COBRA PzF) stent might safely allow for a very short duration of triple therapy in patients taking oral anticoagulation (OAC) who undergo coronary stenting.METHODS:...

Cite
Colleran R, Joner M, Cutlip D, et al. Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE). Cardiovasc Revasc Med. 2021;doi: 10.1016/j.carrev.2021.01.022.
Colleran, R., Joner, M., Cutlip, D., Urban, P., Maeng, M., Jauhar, R., Barakat, M., Michel, J. M., Mehran, R., Kirtane, A. J., Maillard, L., Kastrati, A., Byrne, R. A. (2021). Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE). Cardiovascular revascularization medicine : including molecular interventions, . https://doi.org/10.1016/j.carrev.2021.01.022
Colleran, Róisín, et al. "Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE)." Cardiovascular revascularization medicine : including molecular interventions vol. (2021). doi: https://doi.org/10.1016/j.carrev.2021.01.022
Colleran R, Joner M, Cutlip D, Urban P, Maeng M, Jauhar R, Barakat M, Michel JM, Mehran R, Kirtane AJ, Maillard L, Kastrati A, Byrne RA. Design and rationale of a randomized trial of COBRA PzF stenting to REDUCE duration of triple therapy (COBRA-REDUCE). Cardiovasc Revasc Med. 2021 Jan 22; doi: 10.1016/j.carrev.2021.01.022. Epub 2021 Jan 22. PMID: 33608239.
Copy Download .nbib Format: NLM
Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations.

Circulation

Ybarra LF, Rinfret S, Brilakis ES, Karmpaliotis D, Azzalini L, Grantham JA, Kandzari DE, Mashayekhi K, Spratt JC, Wijeysundera HC, Ali ZA, Buller CE, Carlino M, Cohen DJ, Cutlip DE, De Martini T, Di Mario C, Farb A, Finn AV, Galassi AR, Gibson CM, Hanratty C, Hill JM, Jaffer FA, Krucoff MW, Lombardi WL, Maehara A, Magee PFA, Mehran R, Moses JW, Nicholson WJ, Onuma Y, Sianos G, Sumitsuji S, Tsuchikane E, Virmani R, Walsh SJ, Werner GS, Yamane M, Stone GW, Rinfret S, Stone GW.
PMID: 33523728
Circulation. 2021 Feb 02;143(5):479-500. doi: 10.1161/CIRCULATIONAHA.120.046754. Epub 2021 Feb 01.

Over the past 2 decades, chronic total occlusion (CTO) percutaneous coronary intervention has developed into its own subspecialty of interventional cardiology. Dedicated terminology, techniques, devices, courses, and training programs have enabled progressive advancements. However, only a few randomized trials...

Cite
Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation. 2021;143(5):479-500doi: 10.1161/CIRCULATIONAHA.120.046754.
Ybarra, L. F., Rinfret, S., Brilakis, E. S., Karmpaliotis, D., Azzalini, L., Grantham, J. A., Kandzari, D. E., Mashayekhi, K., Spratt, J. C., Wijeysundera, H. C., Ali, Z. A., Buller, C. E., Carlino, M., Cohen, D. J., Cutlip, D. E., De Martini, T., Di Mario, C., Farb, A., Finn, A. V., Galassi, A. R., Gibson, C. M., Hanratty, C., Hill, J. M., Jaffer, F. A., Krucoff, M. W., Lombardi, W. L., Maehara, A., Magee, P. F. A., Mehran, R., Moses, J. W., Nicholson, W. J., Onuma, Y., Sianos, G., Sumitsuji, S., Tsuchikane, E., Virmani, R., Walsh, S. J., Werner, G. S., Yamane, M., Stone, G. W., Rinfret, S., Stone, G. W. (2021). Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation, 143(5), 479-500. https://doi.org/10.1161/CIRCULATIONAHA.120.046754
Ybarra, Luiz F, et al. "Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations." Circulation vol. 143,5 (2021): 479-500. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.046754
Ybarra LF, Rinfret S, Brilakis ES, Karmpaliotis D, Azzalini L, Grantham JA, Kandzari DE, Mashayekhi K, Spratt JC, Wijeysundera HC, Ali ZA, Buller CE, Carlino M, Cohen DJ, Cutlip DE, De Martini T, Di Mario C, Farb A, Finn AV, Galassi AR, Gibson CM, Hanratty C, Hill JM, Jaffer FA, Krucoff MW, Lombardi WL, Maehara A, Magee PFA, Mehran R, Moses JW, Nicholson WJ, Onuma Y, Sianos G, Sumitsuji S, Tsuchikane E, Virmani R, Walsh SJ, Werner GS, Yamane M, Stone GW, Rinfret S, Stone GW. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation. 2021 Feb 02;143(5):479-500. doi: 10.1161/CIRCULATIONAHA.120.046754. Epub 2021 Feb 01. PMID: 33523728.
Copy Download .nbib Format: NLM
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

BACKGROUND: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021;245:19-28doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American heart journal, 24519-28. https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose." American heart journal vol. 245 (2021): 19-28. doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
Procedural Myocardial Infarction: Definitions Everywhere, But Not Any That May Fit.

Journal of the American College of Cardiology

Cutlip DE.
PMID: 33004128
J Am Coll Cardiol. 2020 Oct 06;76(14):1640-1643. doi: 10.1016/j.jacc.2020.08.024.

No abstract available.

Cite
Cutlip DE. Procedural Myocardial Infarction: Definitions Everywhere, But Not Any That May Fit. J Am Coll Cardiol. 2020;76(14):1640-1643doi: 10.1016/j.jacc.2020.08.024.
Cutlip, D. E. (2020). Procedural Myocardial Infarction: Definitions Everywhere, But Not Any That May Fit. Journal of the American College of Cardiology, 76(14), 1640-1643. https://doi.org/10.1016/j.jacc.2020.08.024
Cutlip, Donald E. "Procedural Myocardial Infarction: Definitions Everywhere, But Not Any That May Fit." Journal of the American College of Cardiology vol. 76,14 (2020): 1640-1643. doi: https://doi.org/10.1016/j.jacc.2020.08.024
Cutlip DE. Procedural Myocardial Infarction: Definitions Everywhere, But Not Any That May Fit. J Am Coll Cardiol. 2020 Oct 06;76(14):1640-1643. doi: 10.1016/j.jacc.2020.08.024. PMID: 33004128.
Copy Download .nbib Format: NLM
Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01; doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate the...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose. Am Heart J. 2021;doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose. American heart journal, . https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose." American heart journal vol. (2021). doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and Design of the Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T) Trial: A Prospective, Multi-center, Double-blind, Randomized Controlled Trial Evaluating Reductions in Postoperative Bleeding with Intraoperative Removal of Ticagrelor by the DrugSorb™-ATR Device in Patients Undergoing Cardiothoracic Surgery within 48hrs from Last Ticagrelor Dose. Am Heart J. 2021 Nov 01; doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose.

American heart journal

Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN.
PMID: 34736855
Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01.

BACKGROUND: Ticagrelor is often administered to patients with acute coronary syndromes. However, when these patients require urgent or emergent cardiothoracic (CT) surgery the presence of ticagrelor significantly increases surgical bleeding. The goal of the current trial is to evaluate...

Cite
Gibson CM, Mack MJ, Lee VT, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021;245:19-28doi: 10.1016/j.ahj.2021.10.188.
Gibson, C. M., Mack, M. J., Lee, V. T., Schneider, D. J., Sellke, F. W., Ohman, E. M., Thourani, V. H., Doros, G., Kroger, H., Cutlip, D. E., & Deliargyris, E. N. (2021). Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American heart journal, 24519-28. https://doi.org/10.1016/j.ahj.2021.10.188
Gibson, C Michael, et al. "Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose." American heart journal vol. 245 (2021): 19-28. doi: https://doi.org/10.1016/j.ahj.2021.10.188
Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2021 Nov 01;245:19-28. doi: 10.1016/j.ahj.2021.10.188. Epub 2021 Nov 01. PMID: 34736855.
Copy Download .nbib Format: NLM
Anatomic and physiological bases of social blushing: speculations from neurology and psychology.

Behavioural neurology

Cutlip Ii WD, Leary MR.
PMID: 24487133
Behav Neurol. 1993;6(4):181-5. doi: 10.3233/BEN-1993-6402.

Although a common and occasionally troubling reaction, social blushing has received little systematic attention from either medical or behavioral researchers. This article reviews what is known of the physiological and psychological processes that mediate social blushing, and speculates regarding...

Cite
Cutlip Ii WD, Leary MR. Anatomic and physiological bases of social blushing: speculations from neurology and psychology. Behav Neurol. 1993;6(4):181-5doi: 10.3233/BEN-1993-6402.
Cutlip Ii, W. D., & Leary, M. R. (1993). Anatomic and physiological bases of social blushing: speculations from neurology and psychology. Behavioural neurology, 6(4), 181-5. https://doi.org/10.3233/BEN-1993-6402
Cutlip Ii, W D, and Leary, M R. "Anatomic and physiological bases of social blushing: speculations from neurology and psychology." Behavioural neurology vol. 6,4 (1993): 181-5. doi: https://doi.org/10.3233/BEN-1993-6402
Cutlip Ii WD, Leary MR. Anatomic and physiological bases of social blushing: speculations from neurology and psychology. Behav Neurol. 1993;6(4):181-5. doi: 10.3233/BEN-1993-6402. PMID: 24487133.
Copy Download .nbib Format: NLM
Electron microscopy of cell cultures infected with a chlamydial agent causing polyarthritis of lambs.

Infection and immunity

Cutlip RC.
PMID: 16557765
Infect Immun. 1970 May;1(5):499-502. doi: 10.1128/iai.1.5.499-502.1970.

McCoy cell cultures infected with the agent of ovine chlamydial polyarthritis were examined with the electron microscope. The agent was seen as small dense particles (250 to 450 nm) with an eccentric nucleoid and a multilaminated cell wall, as...

Cite
Cutlip RC. Electron microscopy of cell cultures infected with a chlamydial agent causing polyarthritis of lambs. Infect Immun. 1970;1(5):499-502doi: 10.1128/iai.1.5.499-502.1970.
Cutlip, R. C. (1970). Electron microscopy of cell cultures infected with a chlamydial agent causing polyarthritis of lambs. Infection and immunity, 1(5), 499-502. https://doi.org/10.1128/iai.1.5.499-502.1970
Cutlip, R C. "Electron microscopy of cell cultures infected with a chlamydial agent causing polyarthritis of lambs." Infection and immunity vol. 1,5 (1970): 499-502. doi: https://doi.org/10.1128/iai.1.5.499-502.1970
Cutlip RC. Electron microscopy of cell cultures infected with a chlamydial agent causing polyarthritis of lambs. Infect Immun. 1970 May;1(5):499-502. doi: 10.1128/iai.1.5.499-502.1970. PMID: 16557765; PMCID: PMC415931.
Copy Download .nbib Format: NLM
Massive hemoperitoneum without peritoneal signs: An unusual presentation of omental ectopic rupture. A case report.

Case reports in women's health

Van Antwerp E, Schick S, Cutlip H, Turner J, Hott J.
PMID: 34094887
Case Rep Womens Health. 2021 May 15;31:e00327. doi: 10.1016/j.crwh.2021.e00327. eCollection 2021 Jul.

BACKGROUND: Extrauterine ectopic pregnancy is a rare form of ectopic pregnancy, accounting for roughly 1:10,000-30,000 of all pregnancies. Primary omental pregnancy is the least common form of abdominal ectopic pregnancies, making it extremely rare. Typical presentation includes pelvic pain,...

Cite
Van Antwerp E, Schick S, Cutlip H, et al. Massive hemoperitoneum without peritoneal signs: An unusual presentation of omental ectopic rupture. A case report. Case Rep Womens Health. 2021;31:e00327doi: 10.1016/j.crwh.2021.e00327.
Van Antwerp, E., Schick, S., Cutlip, H., Turner, J., & Hott, J. (2021). Massive hemoperitoneum without peritoneal signs: An unusual presentation of omental ectopic rupture. A case report. Case reports in women's health, 31e00327. https://doi.org/10.1016/j.crwh.2021.e00327
Van Antwerp, Emily, et al. "Massive hemoperitoneum without peritoneal signs: An unusual presentation of omental ectopic rupture. A case report." Case reports in women's health vol. 31 (2021): e00327. doi: https://doi.org/10.1016/j.crwh.2021.e00327
Van Antwerp E, Schick S, Cutlip H, Turner J, Hott J. Massive hemoperitoneum without peritoneal signs: An unusual presentation of omental ectopic rupture. A case report. Case Rep Womens Health. 2021 May 15;31:e00327. doi: 10.1016/j.crwh.2021.e00327. eCollection 2021 Jul. PMID: 34094887; PMCID: PMC8167815.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries